Cyclosporin-induced hypertension is a major complication of immunosuppression in transplant recipients but its pathophysiology is only partly understood. Cyclosporin reduces endothelium-dependent vasodilation and increases endothelin synthesis and release, which may contribute to this hypertension. We examined the effects of: (1) 
Introduction
Cyclosporin A (CsA) is a cyclic 11-amino acid peptide produced by the fungi Cylindrocarpon lucidum Booth and Tolypocladium inflatum Gams. 1 It is a potent immunosuppressant which prevents organ rejection in transplant patients. CsA administration causes a dose-related hypertension. 2, 3 CsA damages the endothelium [4] [5] [6] and therefore may alter endothelial-derived substances.
Nitric oxide (NO) is synthesised in the vascular endothelium from the amino acid L-arginine by three enzymes collectively known as NO synthases. 7, 8 L-arginine analogues such as N-nitro-Larginine (NOLA) can inhibit production of NO from L-arginine by competing for NO synthase. CsA exposure in vitro reduces endothelium-dependent vasorelaxation 5, 9 attributed to decreased NO activity in resistance vessels 10 and decreased NO production. 4 Endothelin-1 (ET-1) is a potent vasoconstrictor acting via vascular smooth muscle ETA and ETB receptors. 11 CsA treatment has been shown to cause an increase in ET synthesis in vivo in the rat 12 and from cultured human 13 and rat 14 endothelial cells in vitro. We recently reported that ET receptor antagonism lowers blood pressure (BP) in CsA-hypertensive animals. 15, 16 This paper reports the effects of: (1) No enhancement by exogenous L-arginine administration; and (2) chronic endothelin receptor antagonism with bosentan 15 in a rat and primate model of CsAinduced hypertension. 
Materials and methods

Animals
Female Wistar rats (approximately 250 g) were obtained from the Biological Research Laboratories, Austin and Repatriation Medical Centre. Rats were housed at 24°C in a 12 h day/night cycle with food (standard rat chow, 0.6% NaCl, Lismore, NSW, Australia) and water ad libitum.
Male and female marmosets (Callithrix jacchus) bred in an established marmoset colony (Department of Obstetrics and Gynaecology, University of Melbourne, Royal Women's Hospital, Carlton, Australia) aged between 3-8 years and weighing 300-500 g were studied. Marmosets (n = 10) were housed at 26°C and were fed pellets (standard cat chow, Whiskettes, Sydney, NSW, Australia), fresh fruit and vegetables ad libitum.
CsA-induced hypertension
Rats received either CsA (10 mg/kg/day dissolved in polyvinylpyrrollidone (PVP), subcutaneously) or PVP alone (0.4 ml/day, subcutaneously) for 30 days according to previous published methods. 15, 16 Tail cuff systolic BP (IITC Life Science, Woodland Hills, CA, USA) was measured twice weekly and body weight was measured weekly.
To accustom the marmosets to BP measurements, they were restrained in a specially designed chair for a few minutes each day for 1-2 weeks and tail cuff BP was obtained according to previously published methods. 15, 17 After this acclimatisation period tail cuff systolic BP was recorded (model 229 amplifier and model 38L flatbed recorder, IITC Life Science) for 3 days before drug treatment began, to obtain baseline readings. Body weight was measured weekly during the study. CsA (30 mg/kg/day, dissolved in 0.5 ml olive oil) was given orally to all marmosets for 20 days according to previously published methods. 15 Tail cuff systolic BP was measured 3 times weekly during the first 14 days.
Rat studies: experiment 1
To determine whether increasing substrate availability might increase NO production and so lower BP during the last 7 days of CsA or PVP treatment rats received either L-arginine (250 mg/kg/day in saline, i.p.) or saline alone (0.6 ml/day, i.p.). An alternative group received NOLA (25 mg/kg/day in saline, i.p.) to determine whether NO synthase antagonism would increase BP as in other animal models. 18, 19 The hypothesis being tested was that if NO synthase activity was already abolished by CsA then NOLA would have no effect on BP. Tail cuff systolic BP was measured daily. On day 6 of L-arginine treatment, rats were housed in metabolic cages for 24 h for the collection of urine. Water intake and urine output were measured.
At the end of treatment rats were killed by decapitation and trunk blood was collected for the measurement of CsA concentrations using the Incstar Cyclo-Trac SP-whole blood radioimmunoassay kit (Incstar corporation, USA). Plasma creatinine was measured using a Beckman Automated Stat Routine Analyser 8 (Beckman instruments, Palo Alto, CA, USA).
Urine nitrite/nitrate concentrations, as an indirect measure of NO production and excretion, were measured using the Griess reagent. 20 The nitrate reductase and imidazole buffer were obtained from Boehringer Mannheim Australia Pty Ltd (Box Hill, Victoria, Australia). Samples were incubated with nitrate reductase in the presence of NADPH to reduce all nitrate to nitrite. After incubation, total nitrite in samples was measured using the Griess reagent and measured at 540 nm using a plate reader. Known concentrations of sodium nitrite were used to create a standard curve.
Rat studies: experiment 2
As described previously 15 during the last 5 days of CsA or vehicle treatment rats received either bosentan (100 mg/kg/day in arabic gum, by gavage, CsA group: n = 14 and vehicle group: n = 10) or arabic gum alone (0.6 ml/day, by gavage, CsA group: n = 14 and vehicle group: n = 15). Tail cuff systolic BP was measured daily during these 5 days. At the end of treatment, rats were anaesthetised with methohexitone sodium (60 mg/kg, intraperitoneally, supplemented as required) for the insertion of a polyethylene carotid artery catheter (P45, Dural Plastics and Engineering, Sydney, NSW, Australia). At least 24 h after surgery mean arterial pressure was measured in conscious rats using a BP transducer (model DPT 3003-S, Peter von Berg, Germany) calibrated and attached to the intra-arterial catheter. Transducer signals were pre-amplified before analog-digital conversion (Maclab/8TM, Analog Digital Instruments Pty Ltd, Sydney, NSW, Australia) for the recording and storage of data.
Marmoset studies: experiment 1
During days 15-21 of CsA treatment marmosets either received L-arginine (250 mg/kg/day, p.o., in water) or water alone, as a control. Systolic BP was measured daily and the average recordings for days 16-18 and days 19-21 were obtained for each animal. This average was taken as the value for that animal at that time. At the end of treatment (day 21), approximately 2 ml blood was taken from the femoral vein for the measurement of blood CsA and plasma creatinine concentrations and body weight was recorded before marmosets were killed by anaesthetic overdose with 9 mg of alphaxalone (Saffan, Pitman-Moore, NSW, Australia) administered intramuscularly.
Marmoset studies: experiment 2
During days 15-21 of CsA treatment marmosets either received bosentan (100 mg/kg/day, p.o. in arabic gum) or arabic gum alone, as a control. 15 Systolic BP was measured daily and the average recordings for days 16-18 and days 19-21 were obtained for each animal. This average was taken as the value for that animal at that time. At the end of treatment (day 21), approximately 2 ml blood was taken from the femoral vein for the measurement of blood CsA and plasma creatinine concentrations and body weight was recorded before marmosets were killed by anaesthetic overdose with 9 mg of alphaxalone (Saffan, Pitman-Moore) administered intramuscularly.
Statistics
Values are expressed as means Ϯ s.e.m. The effects of bosentan and L-arginine administration on tail cuff systolic BP were subjected to a two-way repeated measures analysis of variance. The factors were treatment and time, with time the repeated measure. Post hoc analysis of individual time points was performed using the Newman-Keuls test. Blood CsA concentrations, plasma creatinine, and tissue weights in the rat studies were analysed by two factor analysis of variance with CsA/control and Larginine/NOLA/saline being the factors. Tissue weights and blood CsA and plasma creatinine concentrations in the marmoset study were analysed by unpaired t-tests. Statistical significance was taken when P Ͻ 0.05.
Results
Rat studies: experiment 1
Baseline BPs for the control and CsA-treated rats did not differ (126 Ϯ 2 vs 126 Ϯ 3 mm Hg). At week 3 systolic BP in the CsA-treated rats was significantly elevated (133 Ϯ 2 mm Hg, P Ͻ 0.05) compared to the control rats (121 Ϯ 4 mm Hg, Figure 1a ). At day 6 of L-arginine administration BP was lowered in the normotensive control rats to 104 Ϯ 6 mm Hg and to a greater extent in the CsA-hypertensive rats to 111 Ϯ 6 mm Hg. The BP in rats treated with NOLA was significantly raised by the end of week 4 (vehicle-treated 134 Ϯ 2 mm Hg; CsA-treated 142 Ϯ 3 mm Hg) compared to week 3 (vehicletreated 124 Ϯ 2 mm Hg; CsA-treated 133 Ϯ 2 mm Hg) consistent with residual NO synthase activity that was antagonised with NOLA ( Figure  1b) .
Blood CsA concentration was raised in the CsAtreated groups and not detectable in the control rat groups. Plasma and urine creatinine did not differ between groups. Urine volume was not significantly different between groups.
Urinary nitrite/nitrate excretion and water intake were not altered with L-arginine or NOLA treatment although there was a trend for lower nitrite/nitrate excretion with NOLA (Table 1) . However, CsA caused a significant increase in urinary nitrate/nitrite excretion and a significant decrease in water intake compared to control rats (Table 1) .
Experiment 2
As previously described 15 baseline BPs were similar for the control (126 Ϯ 1.6 mm Hg) and CsA-treated 100 mg/kg bosentan lowered tail cuff systolic BP in the CsA-hypertensive rats to control rat levels (ie, from 134 Ϯ 1 mm Hg to 122 Ϯ 3 mm Hg, P Ͻ 0.01). This fall in systolic BP was confirmed by the measurement of intra-arterial mean BP (MAP) in the four groups of rats (Figure 2a ). Blood CsA concentration was raised in both CsAtreated groups (P Ͻ 0.01) while readings for the con- Figure 2 Column graph shows effects of daily oral administration of gum or bosentan to either control or CsA-treated animals. (a) Daily treatment with bosentan significantly reduced intra-arterial pressure in the CsA-hypertensive Wistar rats to normotensive levels at the end of the treatment. n = 10-15 rats per group. **P Ͻ 0.01 vs CsA/gum group; (b) At the end of treatment, bosentan treatment significantly lowered tail cuff systolic BP compared to the gum-treated group of marmosets. n = 5 marmosets per group. **P Ͻ 0.01 vs CsA/gum group. Modified from Bartholomeusz et al. 16 trol rat groups were below the sensitivity of the assay. 15 There were no differences in plasma creatinine, sodium, potassium and ET-1 concentrations or left ventricular weights between the four rat groups (data not shown).
Marmoset studies: experiment 1
Following a significant rise in BP due to CsA treatment (156 Ϯ 3 mm Hg compared to 120 Ϯ 8 mm Hg at baseline), L-arginine administration caused a fall in BP to control levels by the end of the treatment period (129 Ϯ 5 mm Hg). BP continued to rise in the vehicle-treated group (133 Ϯ 3 mm Hg at baseline compared to 164 Ϯ 4 mm Hg at end of treatment) (Figure 1c ).
Experiment 2
By the end of week 2 CsA raised systolic BP in the marmosets from 133 Ϯ 3 mm Hg (baseline reading) to 156 Ϯ 2 mm Hg (P Ͻ 0.01) in the gum-treated group and 151 Ϯ 7 mm Hg (P Ͻ 0.01) in the bosentan-treated group. 15 There was no difference in the BP between these groups. Systolic BP remained elevated in the gum-treated group by the end of 7 days treatment (157 Ϯ 5 mm Hg), while in the bosentan-treated group BP was lowered to 139 Ϯ 4 mm Hg (P Ͻ 0.01 compared with the gum-treated group) (Figure 2b ). This was not statistically significantly different from their baseline BP before CsA treatment.
Blood CsA was significantly lower in the bosentan-treated group at the end of the experiment compared to the gum-treated group (Table 2, 37.6 Ϯ 9.6 vs 14.4 Ϯ 2.0 nmol/L, P Ͻ 0.05). Plasma creatinine, kidney and left ventricle weights were not significantly different between the groups (Table 2) . Plasma creatinine concentrations from a group of normotensive marmosets (0.045 Ϯ 0.005 mmol/L, n = 5) that did not receive CsA were not different to the CsA-treated group (0.052 Ϯ 0.002 mmol/L, n = 5, Table 2 ) and data from other investigations.
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Discussion
Our results have shown that modulation of the endothelially-derived vasoactive factors NO and ET with L-arginine administration and bosentan respectively, lower BP in CsA-hypertensive rats and marmosets.
It is widely documented that CsA damages the vascular endothelium. 6 Disturbances in endo- thelium-dependent systems might well contribute to CsA-induced hypertension. Several studies have shown reduced endothelium-dependent relaxation in CsA-treated blood vessels in animals 18 and humans. 4 Gerkens et al 5 demonstrated dose-dependent decreases in vasodilator responses to acetylcholine by CsA. However, endothelium-independent relaxations to sodium-nitroprusside were preserved, suggesting a specific effect on the endothelium. Sudhir et al 19 reported that CsA administration impairs the release of NO in conductance and resistance coronary arteries in dogs. Richards et al 4 found that CsA caused a decrease in spontaneous relaxation and inhibition of acetylcholine-induced relaxation in human subcutaneous resistance vessels.
It has been suggested that CsA inhibits inducible NO synthase at the mRNA level in rat vascular smooth muscle cells. 21 This group found that CsA did not decrease iNOS mRNA stability but rather affected transcription. In contrast some studies have shown either no change or an elevation of NOS expression or activity. 22 Lopez-Ongil et al 22 reported no deficit in endothelial constitutive NOS expression and a slight elevation in NOS activity after CsA exposure in bovine aortic endothelial cells.
The present study found a significant difference in urinary nitrite/nitrate excretion between the control and CsA-treated groups. This finding is in contrast with Bobadilla et al 23 who suggested that NO production was not reduced with CsA-treatment. However, we did not see any change in urinary nitrite/nitrate excretion after L-arginine or NOLA treatment. Perhaps it may be better to focus on local intrarenal, rather than urinary measurements, for more accurate measures.
Several groups have reported on the beneficial effect of L-arginine administration on CsA-induced nephrotoxicity in rats. [24] [25] [26] Bloom et al 25 and Gallego et al 18 found that L-arginine reversed CsA-induced vasoconstriction in anaesthetised and conscious rats. Gallego also showed that simultaneous administration of L-arginine with CsA significantly prevented the toxic effects of CsA. Our study showed that L-arginine can significantly lower BP in both rats and marmosets which are CsA-hypertensive. Although, L-arginine did have a slight hypotensive effect in normotensive control rats, the decrease in BP was greater in the CsA-treated group.
We had hypothesised that by increasing the substrate concentration for NO synthase, a greater amount of NO could be synthesised and therefore restore endothelium-dependent vasodilation. However, it has been reported that L-arginine is abundant in the body in concentrations far in excess of the K m for NOS. Therefore, adding it exogenously should not produce more NO. Vallance 27 has described an increase in the presence of endogenous NO synthase inhibitors asymmetric dimethylarginines (ADMA), in states of renal disease. It is possible that ADMA accumulate in CsA-hypertension and inhibit NOS thus increasing BP. Exogenous L-arginine might therefore compete for NO synthase with ADMA and so increase NO production. However, Larginine might also be acting through alternate mechanisms.
NOLA had a further hypertensive effect in the CsA-treated rats as well as increasing BP in the vehicle group suggesting that CsA was not completely inhibiting NOS activity directly or indirectly, such that further NOS inhibition was possible. Bobadilla et al 23 found an increase in mean arterial pressure in Wistar rats following N-nitro-Larginine methyl ester (L-NAME, another NOS inhibitor) administration. Interestingly, Bloom et al 25 reported that L-NAME had no further effect on the renal vasoconstriction caused by CsA. Regional variations in NO production due to CsA might explain the difference between these results and our results. Direct measurements of NOS density and activity would help resolve this issue.
As previously reported, 15, 16 acute and chronic ET antagonism can also reduce BP in CsA hypertensive rats and primates. It is known that CsA can increase ET peptide and mRNA in vivo 28 and in vitro. 29 Takeda et al 30 have also shown that ETA receptor antagonism prevents hypertension induced by cyclosporin. These results are all consistent with upregulation of ET production being pathogenetic in CsA-induced hypertension, potentially in addition to reduction in NO production.
In conclusion, our results further support a role for nitric oxide in the pathophysiology of CsAinduced hypertension. Moreover, modulation of these systems might mean L-arginine may be therapeutically beneficial in alleviating this problem.
